Lassa Fever Pipeline Insight

DelveInsight’s, “Lassa Fever Pipeline Insight 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Lassa Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

Lassa Fever Disease Understanding

Lassa Fever Overview

Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus, an arenavirus endemic in parts of West Africa, particularly Nigeria, Sierra Leone, Liberia, and Guinea. The disease was first identified in 1969 in Lassa, Nigeria. Most infections are mild or asymptomatic, but severe disease can involve multi-organ dysfunction, bleeding, shock, and death. Common symptoms include fever, weakness, headache, sore throat, chest pain, vomiting, diarrhea, facial swelling, and hearing loss. Lassa fever is considered a major public health concern because of its epidemic potential and high burden in endemic regions.

Lassa fever is caused by the Lassa virus, which is primarily transmitted to humans through exposure to urine, feces, saliva, or other excreta of infected multimammate rats (Mastomys natalensis), the natural reservoir host. Human infection commonly occurs through contaminated food, household items, or inhalation of aerosolized particles. Person-to-person transmission may also occur through direct contact with blood, tissues, secretions, or bodily fluids of infected individuals, especially in healthcare settings without proper infection control measures. Laboratory exposure and contaminated medical equipment can further contribute to spread.

After entering the body, Lassa virus infects antigen-presenting cells such as macrophages and dendritic cells, enabling widespread viral dissemination through the bloodstream to multiple organs including the liver, spleen, kidneys, and vascular endothelium. The virus suppresses innate immune responses and interferon signaling, allowing uncontrolled viral replication. Endothelial dysfunction, vascular leakage, impaired platelet function, and cytokine dysregulation contribute to hemorrhage, hypotension, and organ damage. Severe disease may result in shock, respiratory failure, neurological complications, and death. Sensorineural hearing loss is a common long-term complication among survivors.

Diagnosis of Lassa fever is challenging because early symptoms resemble many other tropical infections such as malaria or typhoid fever. Laboratory confirmation is typically performed using reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA) for antigen or antibody detection, or viral isolation in specialized laboratories. Blood tests may reveal thrombocytopenia, elevated liver enzymes, and coagulation abnormalities. Early diagnosis is essential for initiating supportive therapy and infection control measures. Clinicians also evaluate travel history, exposure risk, and epidemiological context when assessing suspected cases.

Treatment of Lassa fever primarily involves supportive care, including fluid and electrolyte management, oxygen therapy, blood pressure support, and treatment of complications such as bleeding or secondary infections. Early administration of intravenous ribavirin has shown benefit in reducing mortality when given during the initial stages of illness. Patients with severe disease may require intensive care management. Strict infection prevention and control practices are critical to prevent nosocomial transmission. Preventive measures include rodent control, safe food storage, environmental sanitation, and avoiding contact with infected bodily fluids. Several vaccines and antiviral therapies are currently under investigation for improved prevention and treatment.

"Lassa Fever- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lassa Fever pipeline landscape is provided which includes the disease overview and Lassa Fever treatment guidelines. The assessment part of the report embraces, in depth Lassa Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lassa Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Lassa Fever Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lassa Fever R&D. The therapies under development are focused on novel approaches to treat/improve Lassa Fever.

Lassa Fever Emerging Drugs Analysis

This segment of the Lassa Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lassa Fever Emerging Drugs

Favipiravir: FUJIFILM Toyama Chemical Co., Ltd.

Favipiravir (brand name Avigan®) is a broad-spectrum antiviral drug, a severe viral hemorrhagic disease caused by Lassa virus. The drug is a pyrazinecarboxamide derivative that acts by selectively inhibiting viral RNA-dependent RNA polymerase (RdRp), thereby blocking replication of RNA viruses including arenaviruses such as Lassa virus. Favipiravir has demonstrated antiviral activity against Lassa virus in preclinical and clinical studies and has been evaluated as an alternative to ribavirin for Lassa fever treatment. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of Lassa Fever.

Further product details are provided in the report……..

Lassa Fever Drug Therapeutic Assessment

This segment of the report provides insights about the different Lassa Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Lassa Fever Players in Lassa Fever  

There are approx. 3+ key companies which are developing the therapies Lassa Fever. The companies which have their Lassa Fever drug candidates in the most advanced stage, i.e. Phase II/III include, FUJIFILM Toyama Chemical Co., Ltd., and others.

Lassa Fever Clinical Trial Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Lassa Fever Drug Route of Administration

Lassa Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Lassa Fever Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Lassa Fever Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lassa Fever Clinical Trial Activities

The Lassa Fever Pipeline report provides insights into Lassa Fever Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Lassa Fever therapeutic drugs key players involved in developing key drugs.

Lassa Fever Pipeline Development Activities

The Lassa Fever Clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lassa Fever drugs.

Lassa Fever Pipeline Report Insights

• Lassa Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lassa Fever Pipeline Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered In The Lassa Fever Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lassa Fever drugs?
• How many Lassa Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lassa Fever?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lassa Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lassa Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Lassa Fever Key Companies

• FUJIFILM Toyama Chemical Co., Ltd.
• Arisan Therapeutics, Inc

Lassa Fever Key Products

• Favipiravir
• ARN-75039